Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Get the latest international news and world events from around the world.

Log in for authorized contributors

Arthritis Cure BREAKTHROUGH: Regrow Young Cartilage

Stanford published a paper in Science showing they regrew joint cartilage in aging mice — and in human tissue samples taken from knee-replacement patients — by blocking a single enzyme called 15-PGDH. It’s being hyped as the end of knee and hip replacement surgery. The science is real. The hype is getting ahead of what the paper actually says.

This episode walks through the study itself — the three experiments, the surprising mechanism (which doesn’t involve stem cells at all), and the actual clinical timeline.

Bottom line: the mechanism is a genuinely new paradigm for tissue regeneration. The human osteoarthritis trial? \.

Weird rings of DNA fuel cancers. This scientist leads the effort to target them

Scientist Paul Mischel is championing the importance of odd rings of DNA in tumors—and their promise as targets for cancer therapy.

Learn more on DNADay.

Paul Mischel and others are testing therapies for rogue genetic loops that drive tumor evolution and growth.

The AI Paradox: Cure or Poison?

Technology promised simplicity. It delivered complexity.

AI promised resolution. It is delivering acceleration.

The paradox is not a bug. It is the feature. And the question is what we choose to do about it.

This week I published a new essay, It is the argument I have been circling for a decade, finally in one place.

The short version: as AI’s capabilities grow, so do the risks. They are not separate variables. They climb the same curve. A more powerful model can cure more diseases and design more weapons. A smarter agent can book your travel and drain your bank account. Capability is leverage. Leverage is indifferent to ethics.

Every time we raise the ceiling of what AI can do, we raise the floor of what can go wrong.

We still have the how. We are drowning in the what. What we have neglected, almost completely, is the why.

Continue reading “The AI Paradox: Cure or Poison?” | >

‘How worlds are created’: University of Washington astronomers find evidence of planets clashing

Anastasios Tzanidakis, a UW doctoral student in astronomy, was looking through data from 2020 when he noticed an otherwise unremarkable star’s light dimming and then fluctuating wildly. What he found was evidence of planets colliding — which could shed light on how planets, like ours, form.

Mitochondria in Alzheimer’s Disease Pathogenesis

Alzheimer’s disease (AD) is a progressive and incurable neurodegenerative disorder that primarily affects persons aged 65 years and above. It causes dementia with memory loss and deterioration in thinking and language skills. AD is characterized by specific pathology resulting from the accumulation in the brain of extracellular plaques of amyloid-β and intracellular tangles of phosphorylated tau. The importance of mitochondrial dysfunction in AD pathogenesis, while previously underrecognized, is now more and more appreciated. Mitochondria are an essential organelle involved in cellular bioenergetics and signaling pathways. Mitochondrial processes crucial for synaptic activity such as mitophagy, mitochondrial trafficking, mitochondrial fission, and mitochondrial fusion are dysregulated in the AD brain. Excess fission and fragmentation yield mitochondria with low energy production.

Applications of Spatial Transcriptomics in Ischemic Stroke Research

Acute ischemic stroke is a complex disorder in which the damage goes beyond neuronal loss and involves dynamic responses from glial, vascular, stromal, and immune cells. Spatial transcriptomics (ST) has become a powerful tool to study these processes by preserving tissue architecture while revealing detailed gene expression patterns. This review describes how ST has advanced the understanding of cellular changes after stroke, focusing on microglia, astrocytes, and oligodendrocytes to showcase the complexity of stroke pathobiology.

Rheumatoid Factor: Diagnostic and Prognostic Performance and Therapeutic Implications in Rheumatoid Arthritis

Rheumatoid factor (RF) is the first autoantibody identified in rheumatoid arthritis (RA) which targets the fragment crystallizable (Fc) region of immunoglobulin (Ig) G. Although IgM isotype is predominant, other Ig isotypes, including IgG and IgA, also exist. While RF is not specific to RA, it remains a valuable serological test for diagnosing the disease, as evidenced by its inclusion in the 2010 classification criteria for RA based on elevated serum RF levels. RF is also associated with RA severity, including joint damage and extra-articular manifestations, serving as a poor prognostic factor and aiding in the identification of difficult-to-treat RA. Recent studies have demonstrated that high serum RF levels are associated with a reduced response to tumor necrosis factor (TNF) inhibitors.

How a chemical reaction triggers brain inflammation in Alzheimer’s disease

The brain has its own immune system, which detects threats and mounts a defense. A growing body of evidence has shown that in Alzheimer’s disease, those immune cells are chronically overactivated, causing inflammation that damages the connections between brain cells.

Now, in a preclinical study using human Alzheimer’s brain cells, scientists at Scripps Research have identified a molecular switch—and potential drug target—responsible for driving that chronic inflammation.

The research, published in Cell Chemical Biology on April 23, 2026, centers on a protein called STING, which normally functions as part of the immune system’s early-warning system. In the brains of people with Alzheimer’s, the team discovered that STING undergoes a chemical modification known as S-nitrosylation (or SNO, a reaction involving sulfur, oxygen and nitrogen) that promotes its overactivation. Blocking this chemical change to STING in a mouse model of the disease decreased neuroinflammation.

/* */